Cipla's Goa unit completes USFDA inspection with two observations

Cipla announced that that the USFDA has conducted an inspection at the Company's manufacturing facility in Verna, Goa from 6 to 17 April 2026. The inspection was a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI). On conclusion of the inspection, the Company received two (2) inspectional observations in Form 483.